Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 8 Lymphoid 5 Plasma cell 3 Thoracic 2 Gynecologic 2 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 326 Nivolumab 289 Ipilimumab 260 Cyclophosphamide 194 aldesleukin 145 Interleukin-2 109 fludarabine phosphate 107 Temozolomide 83 fludarabine 81 Dacarbazine 81 Radiotherapy 74 trametinib 73 Vemurafenib 69 dabrafenib 66 Biopsy 65 sargramostim 50 Bevacizumab 50 Radiosurgery 49 Paclitaxel 49 Peripheral Blood Stem Cell Transplantation 48 Magnetic Resonance Spectroscopy 48 Carboplatin 48 Imiquimod 47 Aminolevulinic Acid 47 binimetinib 45 Cisplatin 45 CTLA-4 Antigen 43 cemiplimab 42 Specimen Handling 42 atezolizumab 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × romiplostim × Dermatologic × Clear all

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡